Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 28, Issue 10, Pages 5461-5467Publisher
SPRINGER
DOI: 10.1245/s10434-021-10522-z
Keywords
-
Funding
- Morgan Welch Inflammatory Breast Cancer Research Program
- State of Texas Rare and Aggressive Breast Cancer Research Program Grant
Ask authors/readers for more resources
Inflammatory breast cancer is a rare and aggressive form of breast cancer that requires diagnosis and treatment based on clinical symptoms, with no evidence supporting de-escalation of surgical therapy. Delayed reconstruction is recommended to avoid recurrence and potential delays in adjuvant therapy.
Inflammatory breast cancer (IBC) is a rare and aggressive breast cancer characterized by erythema and edema of at least one-third of the breast. The diagnosis remains a clinical one. Standard of care involves trimodality therapy with anthracycline-based neoadjuvant chemotherapy and human epidermal growth factor receptor 2 (HER2)-directed therapy if HER2 positive, followed by modified radical mastectomy and post-mastectomy radiation therapy to the chest wall in addition to regional nodal basins including supraclavicular and internal mammary nodes. Current evidence does not support de-escalation of surgical therapy in the breast and axilla in IBC, and positive surgical margins have been associated with worse outcomes. Furthermore, sentinel node biopsy for axillary staging has a high false negative rate prohibiting its use in IBC. Delayed reconstruction is recommended for IBC due to a high recurrence rate and a potential for delay in adjuvant therapy. Contralateral prophylactic mastectomy may be considered at the time of delayed reconstruction. In this paper, we discuss available evidence and controversies in the current surgical management of patients with IBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available